NSCLC

ASCO 2021: Lumakras, First Approved KRAS-targeting Cancer Drug, Looks Promising

June 04, 2021

The FDA approved Amgen’s Lumakras (sotorasib) last week, the first drug targeting KRAS-mutated cancer to get the agency’s OK. But the clinical and commercial future of the drug is uncertain.

Black Lung Cancer Patients May Be Missing Out On Era of Targeted Therapy

June 01, 2021

Meta-analysis shows lower prevalence of four known driver mutations among Black lung cancer patients. More research into tumor biology of Black patients might yield targeted therapies that would benefit Black lung cancer patients, says the lead author, Philippos A. Costa, M.D.

Atezolizumab Extends Disease-Free Survival in Patients with PD-L1 Positive Early NSCLC

June 01, 2021

Patients who were PD-L1 positive with early stage non-small-cell lung cancer had better results and a lower risk of death or progression compared to a cohort on best supportive care.

FDA Approves Drug Targeting KRAS Mutation For First Time

May 28, 2021

The FDA gave its first approval today of a cancer drug that targets a KRAS mutation.

FDA Approves J&J's Rybrevant for NSCLC With Certain Kind of EGFR Mutation

May 21, 2021

Precision medicine is getting that much more precise. Today's FDA go-ahead is for a J&J drug that is designed to treat the 2% to 3% of NSCLC patients wiht EGFR exon 20 insertion mutations.

NSCLC Care That Doesn’t Follow NCCN Guidelines is 27% More Costly

May 21, 2021

CVS Health research shows $7,084 cost disadvantage to care that is not "concordant" with National Comprehensive Care Network guidelines.

Lung Cancer Screening Has Had Few Takers. Will Updated Recommendations Make a Difference?

May 20, 2021

A small fraction of those who were eligible under previous U.S. Preventive Services Task Force recommendations were screened with low-dose CT scans. New recommendations will make an additional 6.4 million Americans eligible, but a number of barriers to screening remain.